• Lung cancer represents a major burden worldwide and particularly in China due to air pollution and smoking habits.
• Evidence generation on the safety and effectiveness of new therapies increasingly requires the collection of real world data (RWD).
• However, although it is recognized that a number of clinical databases exist in China, currently no repository of disease-specific databases for the conduct of RW studies on lung cancer has been developed.
OBJECTIVES
• To identify, characterize and assess the usefulness of existing data sources in China for the conduct of observational research in lung cancer.
METHODS

RESULTS
Type of Study Required Characteristics or Data
Prevalence -Cross-sectional data Incidence -Longitudinal data 
Drug utilization -Prescription or drug dispensing -Longitudinal data
CONCLUSION
• Several sources of RWD on lung cancer patients have been identified in China. Although most of them lack disease-specific data elements, electronic medical records and administrative claims databases contain valuable information and can allow the conduct of real-world studies on lung cancer.
• Moreover, a relatively important proportion of data sources identified include information of healthcare utilization constituting valuable resources for pharmacoeconomic analyses. 
